Additional file 1: Figure S1. of MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy

MOESM1 of Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis

Claudio Carini (4805787)
Ewan Hunter (416473)
Aroul Ramadass (4805790)
Jayne Green (182987)
Alexandre Akoulitchev (41353)
Iain McInnes (2063845)
Carl Goodyear (4805793)

January 2018

Additional file 1: Note. Scottish Early Rheumatoid Arthritis inception cohort (SERA). Table S1. Prev...

Additional file 5: Figure S4. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean DAS parameters and DAS responder rates over time in the total population. (PDF 111 kb

Additional file 4: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Mark Genovese (3442910)
Rene Westhovens (11539)
Luc Meuleners (4996577)
Annegret Van der Aa (4996583)
Pille Harrison (4996580)
Chantal Tasset (4996586)
Arthur Kavanaugh (2683)

March 2018

Table S1. Patient-reported outcomes: summary of instruments used and minimally important clinical di...

Additional file 1: of The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study

Anna O’Connor (3117774)
Carter Thorne (3508292)
Hyeon Kang (3508295)
Diane Tin (786343)
Janet Pope (3464090)

August 2016

Comparison of mean change in outcome measurement scores between early period (0–6 weeks) and late pe...

Additional file 2: Figure S1. of Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

Josef Smolen (898)
Annette Szumski (4092064)
Andrew Koenig (3967856)
Thomas Jones (3532070)
Lisa Marshall (240744)

January 2018

Summary of patient disposition in the open-label and double-blind periods. CDAI Clinical Disease Act...

Additional file 1: of Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)

Jamie Sergeant (3566165)
Kimme Hyrich (5514770)
James Anderson (138897)
Kamilla Kopec-Harding (5514773)
Holly Hope (5514767)
Deborah Symmons (3567581)
Anne Barton (23499)
Suzanne Verstappen (3567560)

July 2018

Table S1. Univariable and multivariable analysis of predictors of MTX non-response for those with ac...

Additional file 3: Figure S2. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

ACR20 response rate and mean DAS28â4(ESR) and HAQ-DI over time for patients treated with tofacitin...

Additional file 1: of Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition

M. Schoels (4223311)
F. Alasti (4223314)
J. Smolen (4223305)
D. Aletaha (4223308)

July 2017

Table S1. Formulas of compound scores for RA assessment. Table S2. Baseline characteristics of the L...

Additional file 1: of Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Yoshiya Tanaka (186328)
Kazuteru Wada (6492581)
Yoshinori Takahashi (360065)
Owen Hagino (6492584)
Hubert Hoogstraten (6492587)
Neil Graham (181868)
Hideto Kameda (3399878)

March 2019

Table S1. Summary of clinical response after 4 and 12 weeks of treatment (mITT population plus first...

Additional file 4: Figure S1. of Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Numbers needed to treat for ACR 20/50/70 (a), Disease Activity Score based on C reactive protein and...

Additional file 2: of Methotrexate upregulates circadian transcriptional factors PAR bZIP to induce apoptosis on rheumatoid arthritis synovial fibroblasts

Kohjin Suzuki (4996409)
Kohsuke Yoshida (4996400)
Takeshi Ueha (119906)
Kenta Kaneshiro (4996394)
Ayako Nakai (4996385)
Naonori Hashimoto (4996415)
Koto Uchida (4996403)
Teppei Hashimoto (4996412)
Yoshiko Kawasaki (4996406)
Nao Shibanuma (4996388)
Natsuko Nakagawa (4996391)
Yoshitada Sakai (119945)
Akira Hashiramoto (4996397)

March 2018

Detailed information of patients with RA enrolled in this study. Joint samples obtained from 10 diff...

Additional file 1: Table S1. of IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis

Susanna Lundström (4345954)
Aase Hensvold (3505412)
Dorothea Rutishauser (267236)
Lars Klareskog (4149)
A. Ytterberg (3417980)
Roman Zubarev (154182)
Anca Catrina (246690)

August 2017

Demographic characteristics of the nationwide EIRA cohort. Table S2. Characterized complement pathwa...

Additional file 4: Figure S3. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean change from baseline in ACR component parameters over time in the total population. (PDF 72 kb

Additional file 3: Table S3. of Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Rates reports of improvements meeting or exceeding clinically meaningful and normative values in bot...

Additional file 1: Table S1. of Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors

Marie-Laure Golinski (786439)
Thibault Vandhuick (3441770)
Céline Derambure (786435)
Manuel Fréret (786436)
Matthieu Lecuyer (3441773)
Clément Guillou (786434)
Martine Hiron (3441767)
Olivier Boyer (211211)
Xavier Le Loët (408285)
Olivier Vittecoq (408284)
Thierry Lequerré (786441)

December 2015

Clinical and biological characteristics of rheumatoid arthritis (RA) patients treated with adalimuma...

MOESM1 of Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis

Claudio Carini (4805787)
Ewan Hunter (416473)
Aroul Ramadass (4805790)
Jayne Green (182987)
Alexandre Akoulitchev (41353)
Iain McInnes (2063845)
Carl Goodyear (4805793)

January 2018

Additional file 1: Note. Scottish Early Rheumatoid Arthritis inception cohort (SERA). Table S1. Prev...

Additional file 5: Figure S4. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean DAS parameters and DAS responder rates over time in the total population. (PDF 111 kb

Additional file 4: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Mark Genovese (3442910)
Rene Westhovens (11539)
Luc Meuleners (4996577)
Annegret Van der Aa (4996583)
Pille Harrison (4996580)
Chantal Tasset (4996586)
Arthur Kavanaugh (2683)

March 2018

Table S1. Patient-reported outcomes: summary of instruments used and minimally important clinical di...

Additional file 1: of The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study

Anna O’Connor (3117774)
Carter Thorne (3508292)
Hyeon Kang (3508295)
Diane Tin (786343)
Janet Pope (3464090)

August 2016

Comparison of mean change in outcome measurement scores between early period (0–6 weeks) and late pe...

Additional file 2: Figure S1. of Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

Josef Smolen (898)
Annette Szumski (4092064)
Andrew Koenig (3967856)
Thomas Jones (3532070)
Lisa Marshall (240744)

January 2018

Summary of patient disposition in the open-label and double-blind periods. CDAI Clinical Disease Act...

Additional file 1: of Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)

Jamie Sergeant (3566165)
Kimme Hyrich (5514770)
James Anderson (138897)
Kamilla Kopec-Harding (5514773)
Holly Hope (5514767)
Deborah Symmons (3567581)
Anne Barton (23499)
Suzanne Verstappen (3567560)

July 2018

Table S1. Univariable and multivariable analysis of predictors of MTX non-response for those with ac...

Additional file 3: Figure S2. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

ACR20 response rate and mean DAS28â4(ESR) and HAQ-DI over time for patients treated with tofacitin...

Additional file 1: of Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition

M. Schoels (4223311)
F. Alasti (4223314)
J. Smolen (4223305)
D. Aletaha (4223308)

July 2017

Table S1. Formulas of compound scores for RA assessment. Table S2. Baseline characteristics of the L...

Additional file 1: of Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Yoshiya Tanaka (186328)
Kazuteru Wada (6492581)
Yoshinori Takahashi (360065)
Owen Hagino (6492584)
Hubert Hoogstraten (6492587)
Neil Graham (181868)
Hideto Kameda (3399878)

March 2019

Table S1. Summary of clinical response after 4 and 12 weeks of treatment (mITT population plus first...

Additional file 4: Figure S1. of Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Numbers needed to treat for ACR 20/50/70 (a), Disease Activity Score based on C reactive protein and...

Additional file 2: of Methotrexate upregulates circadian transcriptional factors PAR bZIP to induce apoptosis on rheumatoid arthritis synovial fibroblasts

Kohjin Suzuki (4996409)
Kohsuke Yoshida (4996400)
Takeshi Ueha (119906)
Kenta Kaneshiro (4996394)
Ayako Nakai (4996385)
Naonori Hashimoto (4996415)
Koto Uchida (4996403)
Teppei Hashimoto (4996412)
Yoshiko Kawasaki (4996406)
Nao Shibanuma (4996388)
Natsuko Nakagawa (4996391)
Yoshitada Sakai (119945)
Akira Hashiramoto (4996397)

March 2018

Detailed information of patients with RA enrolled in this study. Joint samples obtained from 10 diff...

Additional file 1: Table S1. of IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis

Susanna Lundström (4345954)
Aase Hensvold (3505412)
Dorothea Rutishauser (267236)
Lars Klareskog (4149)
A. Ytterberg (3417980)
Roman Zubarev (154182)
Anca Catrina (246690)

August 2017

Demographic characteristics of the nationwide EIRA cohort. Table S2. Characterized complement pathwa...

Additional file 4: Figure S3. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean change from baseline in ACR component parameters over time in the total population. (PDF 72 kb

Additional file 3: Table S3. of Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Rates reports of improvements meeting or exceeding clinically meaningful and normative values in bot...

Additional file 1: Table S1. of Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors

Marie-Laure Golinski (786439)
Thibault Vandhuick (3441770)
Céline Derambure (786435)
Manuel Fréret (786436)
Matthieu Lecuyer (3441773)
Clément Guillou (786434)
Martine Hiron (3441767)
Olivier Boyer (211211)
Xavier Le Loët (408285)
Olivier Vittecoq (408284)
Thierry Lequerré (786441)

December 2015

Clinical and biological characteristics of rheumatoid arthritis (RA) patients treated with adalimuma...

MOESM1 of Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis

Claudio Carini (4805787)
Ewan Hunter (416473)
Aroul Ramadass (4805790)
Jayne Green (182987)
Alexandre Akoulitchev (41353)
Iain McInnes (2063845)
Carl Goodyear (4805793)

January 2018

Additional file 1: Note. Scottish Early Rheumatoid Arthritis inception cohort (SERA). Table S1. Prev...

Additional file 5: Figure S4. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean DAS parameters and DAS responder rates over time in the total population. (PDF 111 kb

Additional file 4: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Mark Genovese (3442910)
Rene Westhovens (11539)
Luc Meuleners (4996577)
Annegret Van der Aa (4996583)
Pille Harrison (4996580)
Chantal Tasset (4996586)
Arthur Kavanaugh (2683)

March 2018

Table S1. Patient-reported outcomes: summary of instruments used and minimally important clinical di...

Additional file 1: Figure S1. of MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy

Abstract

Extracted data

Additional file 1: Figure S1. of MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy

Abstract

Extracted data

Related items

Related items